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Abstract
Rationale: Primary ciliary dyskinesia (PCD), a genetically
heterogeneous, recessive disorder of motile cilia, is associated with
distinct clinical features. Diagnostic tests, including ultrastructural
analysis of cilia, nasal nitric oxide measurements, and molecular
testing for mutations in PCD genes, have inherent limitations.
Objectives: To define a statistically valid combination of
systematically defined clinical features that strongly associates with
PCD in children and adolescents.
Methods: Investigators at seven North American sites in the
Genetic Disorders of Mucociliary Clearance Consortium
prospectively and systematically assessed individuals (aged 0–18 yr)
referred due to high suspicion for PCD. The investigators defined
specific clinical questions for the clinical report form based on expert
opinion. Diagnostic testing was performed using standardized
protocols and includednasal nitric oxidemeasurement, ciliary biopsy
for ultrastructural analysis of cilia, and molecular genetic testing for
PCD-associated genes. Final diagnoses were assigned as “definite
PCD” (hallmark ultrastructural defects and/or two mutations in a
PCD-associated gene), “probable/possible PCD” (no ultrastructural
defect or genetic diagnosis, but compatible clinical features and nasal
nitric oxide level in PCD range), and “other diagnosis or undefined.”
Criteria were developed to define early childhood clinical features on
the basis of responses to multiple specific queries. Each defined
feature was tested by logistic regression. Sensitivity and specificity
analyses were conducted to define the most robust set of clinical
features associated with PCD.
Measurements and Main Results: From 534 participants
18 years of age and younger, 205 were identified as having
“definite PCD” (including 164 with two mutations in a PCD-
associated gene), 187 were categorized as “other diagnosis or
undefined,” and 142 were defined as having “probable/possible
PCD.” Participants with “definite PCD” were compared with the
“other diagnosis or undefined” group. Four criteria-defined
clinical features were statistically predictive of PCD: laterality
defect; unexplained neonatal respiratory distress; early-onset,
year-round nasal congestion; and early-onset, year-round wet
cough (adjusted odds ratios of 7.7, 6.6, 3.4, and 3.1, respectively).
The sensitivity and specificity based on the number of criteria-
defined clinical features were four features, 0.21 and 0.99,
respectively; three features, 0.50 and 0.96, respectively; and two
features, 0.80 and 0.72, respectively.
Conclusions: Systematically defined early clinical features could
help identify children, including infants, likely to have PCD.
Clinical trial registered with ClinicalTrials.gov (NCT00323167).
Keywords: primary ciliary dyskinesia; clinical features; laterality
defects; neonatal respiratory distress
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Primary ciliary dyskinesia (PCD) is an
inherited disorder characterized by motile
ciliary dysfunction resulting in an array
of clinical manifestations, including
chronic rhinosinusitis, middle ear
effusions, laterality defects, infertility,
and chronic bronchitis leading to
bronchiectasis. The incidence of PCD is
estimated at 1 in 15,000–20,000 live births,
based on the prevalence of situs inversus
totalis and bronchiectasis (1, 2). Few
patients carry a well-established diagnosis,
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which reflects the limited ability to identify
and definitively diagnose affected
individuals. Therefore, the actual
incidence may be higher than these
estimates. While the clinical spectrum of
PCD has been described for decades,
recent literature continues to redefine the
phenotype (3–10).
Historically, the diagnosis of PCD
relied on the combination of clinical
features and ultrastructural analysis of
respiratory cilia (11–13), which requires
specialized expertise for tissue collection,
processing, and performing and
interpreting transmission electron
micrography. Ultrastructural changes in
cilia may be specific for PCD, but they
can also overlap with acquired changes
due to exposure to viral infection or
environmental pollutants. Moreover,
nearly one-third of affected individuals
have normal ciliary ultrastructure (8).
The clinical phenotype of PCD has
characteristics in common with other
conditions, which can cause diagnostic
delays, especially if the patients do not
have the classical features, such as organ
laterality defects, and this delay may lead
to poorer outcomes for patients (3).
Past clinical criteria for diagnosis
were based on available evidence and
expert opinion (14). Recent studies have
advanced understanding of the spectrum
of clinical phenotypes and have identified
new diagnostic tests, including the
emergence of genetic testing for PCD
(15). The development of our large
multicenter collaborative group in
North America provides an opportunity
for diagnostic standardization in
children and adolescents. In this paper,
we describe a prospective study that
delineates characteristic early childhood
clinical features, alone or in combination,
that are predictive of PCD among infants
and children referred with high suspicion
of PCD. We propose that systematic
evaluation of these clinical markers
helps discriminate individuals, including
infants, likely to have PCD from
unaffected children, thereby identifying
individuals who require more definitive
diagnostic genetic and physiologic
testing (4).
Methods
Study Sites and Participants
Investigators at seven North American
sites in the Genetic Disorders of
Mucociliary Clearance Consortium
systematically and prospectively evaluated
pediatric participants who were referred
because of high suspicion for PCD.
Some participants had a preexisting
diagnosis of PCD but had not had a
full systematic assessment. Evaluation
included comprehensive collection of
clinical information using standardized
case report forms. Standard operating
procedures defined all details of
evaluation, including performance of
diagnostic tests and assignment into
diagnostic categories.
The investigators defined the clinical
questions and corresponding answers for
the clinical report form based on expert
opinion before initiation of the study.
Specific queries from case report forms
were used to define criteria for PCD-
specific clinical features, including
neonatal respiratory distress, otitis media,
cough, nasal congestion, and laterality
defects. Bronchiectasis and sinusitis could
not be systematically assessed, because
computed tomography of the chest and
paranasal sinuses was not performed in all
children. Institutional review board
approval was obtained at all sites, and
informed consent and assent were
acquired from parents and from
participants, as appropriate. An
observational safety monitoring board
reviewed the protocol.
Diagnostic Testing
Diagnostic testing included nasal nitric
oxide measurement, ciliary biopsy for
electron microscopy, and molecular
genetic testing for PCD-associated genes.
Nasal nitric oxide measurements were
performed using standardized protocols
(16, 17). Molecular genetic analyses and
electron microscopy were performed by
researchers at one site (University of
North Carolina), who communicated
results to the local sites.
Ciliated epithelial cells were collected
from the inferior surface of the inferior
nasal turbinates and processed for
transmission electron microscopy, as
previously described (4, 6, 18). Three
reviewers evaluated transmission electron
micrographs in a blinded fashion for
PCD-specific ciliary defects, specifically
(1) absent or truncated outer dynein arms
alone, (2) absent outer and inner dynein
arms, (3) absent inner dynein arms with
microtubular disorganization, and (4)
central apparatus or radial spoke defects
with absent or off-center central pair
associated with transpositions of
peripheral doublet. Isolated inner dynein
arm defects were not considered
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diagnostic, except when apparent on
repeat biopsies.
Genetic testing included screening for
the coding regions and splice junctions for
26 PCD-associated genes using established
techniques (6). Loss-of-function variants,
including nonsense, frameshift, and splice
site variants, were considered pathogenic
mutations. Missense variants or in-frame
deletions were considered to be pathogenic
if they were present in the cases carrying
loss-of-function mutations and if the
ultrastructural defects were congruent with
the mutated gene. Missense variants or
in-frame deletions were initially checked
for rarity using public databases and if
predicted to be pathogenic using in silico
programs such as MutationTaster (19).
Then they were checked for conservation
(across species and/or being part of the
functional domains). Segregation analysis
was performed when possible to determine
the phase. Missense variants on both
alleles were considered pathogenic only
if previous reports showed that these
variants caused functional defects or had
been seen in multiple cases.
To assess for alternative diagnoses,
results from prior clinical tests were
recorded in the case report forms, including
sweat chloride test, CFTRmutation analysis,
pH probe and imaging studies to assess
aspiration or gastroesophageal reflux, and
imaging studies of the chest and sinuses.
Additional clinical testing performed as
part of our research protocol, if not done
before the study visit, included sweat
chloride test, complete blood count with
leukocyte differential, and chest radiograph.
Diagnostic Categories
Final diagnoses were assigned by the
investigator at the local site on the basis
of specific findings as directed by standard
operating protocols: “definite PCD”
(hallmark ultrastructural cilia defects
and/or two pathogenic gene mutations),
“probable/possible PCD” (no definitive
structural defect or genetic diagnosis, but a
compatible clinical phenotype and reduced
nasal nitric oxide level in the PCD range),
“other diagnosis” (another etiology
identified), or “undefined” (no etiology
identified). Researchers at the central site
(University of North Carolina) reviewed
the assigned diagnostic category to ensure
that ultrastructural and genetic results
from the central site were accurately
reflected in the database. Challenging cases
were discussed in biweekly telephone
conference calls.
Statistical Analysis
Data were collated and entered in a
web-based database managed by the
data management coordinating center.
Participants with definite PCD were
compared with those with “other diagnosis”
and “undefined,” combined (hereafter
referred to as other/undefined). Fisher’s
exact test or the Wilcoxon rank-sum test
were used to compare demographics and
clinical features between the PCD and
other/undefined groups. Logistic regression
was used to assess the associations of the
five specifically defined clinical criteria
(Figure 1) with PCD.
Diagnostic performance of clinical
criteria was evaluated by assessing
sensitivity, specificity, and weighted and
unweighted receiver operating characteristic
curves. Sensitivity analyses were conducted
to explore external validity (by including
subjects with probable/possible PCD in
the analyses) and to determine whether
diagnostic accuracy would be different in
children with versus without laterality
defects (by testing interactions between each
symptom-based criterion and laterality
status in a logistic regression model).
P values less than 0.05 were considered
statistically significant. All analyses were
performed using SAS version 9.4 software
(SAS Institute, Cary, NC).
Results
Participants
Between June 2006 and September 2012,
a total of 534 participants (aged <18 yr)
were enrolled at seven consortium sites
across North America: Chapel Hill, North
Carolina, the lead site (254 participants);
St. Louis, Missouri (84 participants);
Toronto, Ontario, Canada (70 participants);
Aurora, Colorado (43 participants); Seattle,
Washington (36 participants); Palo Alto,
California (31 participants); and Bethesda,
Maryland (16 participants). Of 534
participants evaluated, 205 were identified
as having “definite PCD” (48% female;
mean age, 7.8 yr), 187 (46% female;
mean age, 7.0 yr) were categorized as
“other disease” (n = 60, including
immunodeficiency, gastroesophageal reflux,
asthma, allergic rhinitis, sinusitis alone,
chronic otitis media alone, and laterality
defect alone) or “undefined” (n = 127)
(Table 1), and 142 were categorized as
having “probable/possible” PCD (46%
female; mean age, 5.8 yr).
The diagnosis in the 205 participants
with “definite PCD” was based on a
hallmark ultrastructural defect (n = 178)
or two mutations in a PCD-associated
gene (n = 164, not mutually exclusive),
including 28 participants who had genetic
diagnoses alone (10 with DNAH11
mutations and 18 with genes associated
with either outer dynein arm or central
apparatus defects but inadequate or
indeterminate ultrastructural analyses)
(Table 2). Of the 164 participants in the
definite PCD group with two mutations in
an associated PCD gene, 128 had two
loss-of-function mutations, 28 had a
loss-of-function mutation with either
a missense variant or an in-frame
deletion fulfilling criteria for pathogenic
mutations, and 8 had missense mutations
on both alleles fulfilling criteria for
pathogenic mutations based on the
previous reports (20–22). Molecular
analysis of the 26 genes was performed
for 174 of the 187 participants in the
other/undefined group. None harbored
biallelic mutations, and eight participants
carried one loss-of-function mutant allele;
however, the gene mutation was not
congruent with the ultrastructural
phenotype.
Demographic and nasal nitric oxide
values recorded at the time of enrollment
are shown in Table 1. There were no
differences in sex, race, ethnicity, or age
for PCD versus other/undefined group.
General clinical features prevalent (.80%)
in both groups were chronic cough, chronic
nasal congestion, and recurrent otitis.
Neonatal respiratory distress was reported
much more frequently among children with
PCD (81% vs. 32%) (Table 3).
To systematically define clinical
features associated with PCD, we asked
additional questions related to each of the
general clinical features to generate more
specific criteria for each (Figure 1). The
specific criteria-defined clinical features
were tested for ability to better discriminate
PCD from the other/undefined group
(Table 4). With the exception of laterality
defects, fulfillment of the specific criteria-
defined clinical feature, compared with the
respective general feature, was associated
with a decrease in the prevalence of the
characteristic in both groups, which was
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disproportionately greater for the other/
undefined group. Likewise, the more
specific criteria-defined clinical features
had decreased sensitivity but greater
specificity than the general clinical
features (Figure 1).
For the more systematically defined
laterality defect, inclusion of laterality
defects other than situs inversus totalis
increased prevalence in both groups
compared with the general query of situs
inversus totalis, resulting in a modest
increase in sensitivity but a slight decrease
in specificity. The four criteria-defined
features that were noted significantly
(P, 0.001) more frequently in PCD
compared with the other/undefined group
were (1) unexplained neonatal respiratory
distress (57% vs. 11%); (2) early-onset,
year-round wet cough (62% vs. 26%); (3)
early-onset, year-round nasal congestion
(74% vs. 40%); and (4) laterality defects
(53% vs. 15%) (Table 3). Adjusted odds
ratio estimates for each of these individual
criteria-defined clinical features were
strong, ranging from 3.1 to 7.7 (Table 3).
The sensitivity and specificity analysis
based on number of criteria-defined
clinical features is shown in Table 5
and Figure 2. The unweighted receiver
operating characteristic curve suggests that if
a subject had any three or four of those
criteria-defined clinical features, the diagnosis
of PCD would be more than 96% specific but
less than 50% sensitive (Table 5). Of note,
combination of the two most predictive
criteria-based clinical features based on
logistic regression, feature 1 (unexplained
Neonatal respiratory distress
Term gestation
Meconium aspiration
Supplemental O2 requirement ≥ 1d 
Chronic cough Chronic nasal congestion Situs inversus totalis
Year-round Other laterality 
defects
Year-round
Wet cough
Began ≤ 6m of age
Began ≤ 6m of age
yes yes
yes
yes yes
yes
yes
yes
yes
yes
yesyes
yes
no
no
no
no no
no
no
no
no
no
no no
no
Sensitivity: 81%
Specificity: 68%
Sensitivity: 57%
Specificity: 89%
Sensitivity: 62%
Specificity: 74%
Sensitivity: 97%
Specificity: 17%
Sensitivity: 97%
Specificity: 19%
Sensitivity: 74%
Specificity: 60%
Sensitivity: 46%
Specificity: 92%
Sensitivity: 53%
Specificity: 85%
Feature 1
Unexplained neonatal
respiratory distress
Feature 2
Early onset, year-round
wet cough
Feature 3
Early onset, year-round
nasal congestion
Feature 4
Laterality defect
Figure 1. Schematic diagram showing general clinical features and series of questions to define criteria-defined clinical features. The four criteria-defined
clinical features most predictive of primary ciliary dyskinesia were unexplained neonatal respiratory distress, early onset, year-round wet cough, early
onset, year-round nasal congestion, and laterality defects. The sensitivity and specificity to identify children and adolescents with primary ciliary dyskinesia
are shown for each general clinical feature and its respective criteria-defined clinical feature. Early onset is defined as onset before 6 months of age;
year-round is defined as occurring in all 12 months of the year; and wet cough is defined as sounds productive even if unable to expectorate sputum.
Table 1. Demographics and nasal nitric oxide values at enrollment for definite primary
ciliary dyskinesia and other/undefined groups
PCD (n = 205) Other/Undefined (n = 187) P Value
Female sex 99 (48%) 86 (46%) 0.686
Race, white 171 (83%) 168 (90%) 0.076
Ethnicity,
non-Hispanic
179 (87%) 168 (90%) 0.526
Age
Median (range), yr 8 (0–18) 7 (0–18) 0.191
Mean6 SD, yr 7.86 5.4 7.06 4.5 0.127
<5 yr, n (%) 75 (37%) 76 (41%) 0.467
Nasal nitric oxide*
Mean6 SD, nl/min 20.96 21.8 (n = 121) 258.36 146.9 (n = 102) ,0.0001
Below cutoff of
77 nl/min†
117 (97%) 1 (0.9%) ,0.0001
Definition of abbreviation: PCD = primary ciliary dyskinesia.
*Limited to participants older than 5 years of age who were able to cooperate with the maneuver.
†Prior studies established a cutoff of 77 nl/min with sensitivity of 98% for PCD (16).
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neonatal respiratory distress), and feature
4 (laterality defect) is predictive of PCD
with a sensitivity of 34% and specificity of
95%. Figure 2 shows receiver operating
characteristic curves based on number of
criteria-defined clinical features that were
present. The unweighted curve for the four
significant criteria-defined clinical features
overlaps well with the weighted curve,
based on the logistic regression coefficient
for all five criteria-defined clinical features,
indicating that assignment of a relative
weight to each feature does not improve
diagnostic accuracy.
In terms of sensitivity analyses, when
participants with probable and possible PCD
were included in the PCD group, sensitivity
and specificity results were similar, though
with lower sensitivity (see Table E1 in the
online supplement). No interaction was
found between laterality status and the
association between the remaining three
clinical criteria and PCD case status (P. 0.10
for each), indicating that the diagnostic
accuracy of these three criteria is similar
among children with and without laterality
defects (data not shown).
Discussion
In this prospective study, we defined
specific clinical features apparent in early
childhood that, alone or in combination,
are predictive of PCD. The best performing
clinical criteria for PCD included
(1) unexplained neonatal respiratory
distress with supplemental oxygen
requirement more than 24 hours in term
infants; (2) early-onset, year-round wet
cough; (3) early-onset, year-round nasal
congestion; and (4) laterality defects. If
three or more of these rigorously defined
clinical features are met, specificity for the
diagnosis is greater than 96%. Moreover,
meeting only one or two of the criteria-
defined clinical features may still warrant
diagnostic testing. Using these four
systematically defined but simple clinical
features, the general clinician may be able
to effectively screen for PCD in early
childhood, thereby leading to earlier
referral for specialized diagnostic testing at
a PCD center while avoiding unnecessary
and costly evaluation of patients unlikely
to have the disease.
The clinical features of PCD can
overlap with other conditions, which
historically has made diagnosis of PCD
challenging. Consortium investigators
evaluated over 500 symptomatic children
who were referred because of high suspicion
for PCD to identify 205 individuals with
definite disease, which underscores the
diagnostic confusion among physicians.
This uncertainty is due largely to relative
inexperience with this rare disease and
lack of familiarity with the limitations of
diagnostic testing, including transmission
electron microscopy, ciliary motility
studies, genetic panels, and nasal nitric
oxide testing. For these reasons, all
subjects evaluated at the participating
sites underwent identical comprehensive
testing with rigorous diagnostic
standards to ensure that the “definite
PCD” group did not include participants
who may have had other respiratory
disorders.
The prevalence of clinical features
in children with PCD enrolled in this
collaborative study was similar to that in
previous studies (3–5, 10); however, none
of those studies assessed use of clinical
features to determine the likelihood of
PCD. The only published prospective study
(23) in which researchers examined clinical
features to identify patients likely to have
PCD also identified neonatal respiratory
distress and laterality defects as strong
indicators, though the authors’ approach
was not as systematic about defining the
clinical features or diagnosis. Our study
population significantly differs from the
clinical population seen by a general
pediatric pulmonologist, since many were
referred specifically for PCD diagnostic
testing. Inclusion criteria for consortium
studies limited enrollment to individuals
for whom referring physicians had a
high suspicion of PCD; consequently,
a high proportion (40.5%) of total
participants had “definite” PCD. Further,
the “other disease” group also had a high
prevalence of clinical features that could
be suggestive of PCD, including laterality
defects.
Table 2. Distribution of ciliary ultrastructural defects and associated primary ciliary
dyskinesia genes with two pathogenic mutations in the 205 participants with “definite”
primary ciliary dyskinesia
Ciliary Defect Mutated Gene Number of Participants (%)
Absent or truncated outer
dynein arms, alone
DNAH5 60
DNAI1 14
DNAI2 5
CCDC114 3
ARMC4 2
Not identified 18
Total 102 (49.8%)
Absent outer and inner
dynein arms
LRRC6 3
HEATR2 6
SPAG1 7
DNAAF1 (LRRC50) 1
DNAAF2 (KTU) 2
ZMYND10 2
DYX1C1 3
Not identified 6
Total 30 (14.6%)
Absent inner dynein
arms with microtubular
disorganization
CCDC39 15
CCDC40 24
Not identified 15
Total 54 (26.3%)
Central apparatus or radial
spoke defects; or inner
dynein arm defect, alone
RSPH4A 6
RSPH9 1
Not identified 2
Total 9 (4.4%)
Normal or indeterminate DNAH11 10
Total 10 (4.9%)
ORIGINAL RESEARCH
Leigh, Ferkol, Davis, et al.: Early Clinical Features of PCD 1309
To achieve the best discrimination of
clinical features to predict which individuals
are likely to have PCD, further definition
of these general clinical features, based on
use of a series of detailed questions, was
required. For instance, chronic cough
alone was a poor discriminator, since
most participants referred for evaluation
presented with cough. However, children
with PCD characteristically had a year-
round, wet or productive cough that began
as a prominent symptom before 6 months of
age. Thus, seasonal, intermittent, or dry cough
is inconsistent with the diagnosis of PCD.
The characteristic chronic cough in
PCD likely compensates for the lack of
effective mucociliary clearance and
thereby leads to some protection for the
airways and lung. Physiologic data have
shown that “effective” coughs may result
in lung clearance almost equal to normal
mucociliary clearance over short time
periods, even in subjects with PCD who
lack clearance at baseline (24). Chronic
airway infection and inflammation
lead to bronchiectasis in almost all
patients by early adulthood, and
pulmonary function testing typically
shows progressive, airflow-obstructive
defects. Clinical and radiographic features
of bronchiectasis develop as the disease
progresses, even in some children at a
very young age (25).
The general clinical feature “neonatal
respiratory distress” was more prevalent
in the “definite PCD” group than in the
“other” group (81% vs. 32%; P, 0.0001;
specificity, 68%). By limiting neonatal
respiratory distress to those requiring
supplemental oxygen for more than
24 hours and eliminating other causes,
such as prematurity and meconium
aspiration (4, 7), the difference between
PCD and other diagnoses led to a more
specific discriminator (56.6% vs. 11.2%;
P, 0.0001; specificity, 89%). Furthermore,
the combination of neonatal respiratory
distress with a laterality defect was an even
stronger predictor, with specificity of 95%.
In past studies, investigators have
reported that patients with PCD present
in the newborn period with significant
respiratory distress, suggesting a potential
link between effective ciliary function
and the clearance of lung liquid in the
neonatal period (26, 27). However, the
association of PCD with newborn
Table 3. Prevalence of general clinical features and criteria-defined clinical features among participants with primary ciliary
dyskinesia versus other/undefined groups and multiple logistic regression model for criteria-defined clinical features
Features Group
General clinical features PCD (n = 205) Other/Undefined
(n = 187)
Adjusted Odds Ratio
(95% Confidence Interval)*
P Value
Neonatal respiratory distress 166 (81%) 59 (32%) 7.8 (4.6–13.4) ,0.0001
Chronic cough 198 (97%) 155 (83%) 2.4 (0.8–6.7) 0.103
Chronic nasal congestion 198 (97%) 151 (81%) 6.2 (2.3–16.9) 0.0004
Situs inversus totalis 95 (46%) 15 (8%) 12.0 (5.6–25.5) ,0.0001
Recurrent otitis 180 (88%) 152 (81%) 1.5 (0.7–3.2) 0.246
Criteria-defined clinical features
(see definitions in Figure 1)
PCD (n = 204†) Other/Undefined
(n = 185‡)
Adjusted Odds Ratio
(95% Confidence Interval)*
P Value
Unexplained neonatal respiratory distress
(feature 1)
116 (57%) 21 (11%) 6.6 (3.5–12.3) ,0.0001
Early-onset, year-round wet cough (feature 2) 128 (62%) 48 (26%) 3.1 (1.7–5.5) 0.0001
Early-onset, year-round nasal
congestion (feature 3)
151 (74%) 74 (40%) 3.4 (1.9–6.3) ,0.0001
Laterality defect (feature 4) 109 (53%) 28 (15%) 7.7 (4.0–14.9) ,0.0001
Multiple ear infections in first 2 yr of life with
sequelae
89 (43%) 66 (35%) 1.0 (0.6–1.8) 0.981
Definition of abbreviation: PCD = primary ciliary dyskinesia.
*Age was adjusted in the model.
†One participant with PCD was missing data for the criteria.
‡Two other/undefined participants were missing data for the criteria.
Table 4. Sensitivity and specificity for each general and criteria-defined clinical feature
Features Sensitivity Specificity
General clinical features (PCD, n = 205; other/undefined,
n = 187)
Neonatal respiratory distress 81% 68%
Chronic cough 97% 17%
Chronic nasal congestion 97% 19%
Situs inversus totalis 46% 92%
Recurrent otitis 88% 19%
Criteria-defined clinical features (see definitions in
Figure 1) (PCD, n = 204*; other/undefined, n = 185†)
Unexplained neonatal respiratory distress (feature 1) 57% 89%
Early-onset, year-round wet cough (feature 2) 62% 74%
Early-onset, year-round nasal congestion (feature 3) 74% 60%
Laterality defect (feature 4) 53% 85%
Multiple ear infections in first 2 yr of life with sequelae 43% 65%
Definition of abbreviation: PCD = primary ciliary dyskinesia.
*One participant with PCD was missing data for the criteria.
†Two other/undefined participants were missing data for the criteria.
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respiratory distress requiring supplemental
oxygen has been underappreciated.
Thus, the diagnosis is often delayed, as
described in a retrospective review in
which the investigators reported that the
mean age of diagnosis was older than
4 years of age (3).
Frequently, the neonatal respiratory
symptoms in infants with PCD are
attributed to an erroneous etiology, such
as transient tachypnea of the newborn,
neonatal pneumonia, or meconium
aspiration, based on limited features of
these disorders and lack of an alternative
diagnosis in the newborn period (7).
Therefore, clinicians need to carefully
scrutinize the neonatal history and chest
imaging findings of patients suspected
to have PCD. Further delineation of
PCD-associated neonatal respiratory
features for pediatricians and neonatologists
could lead to an earlier diagnosis.
Another striking phenotypic feature
that may be detected at birth is a laterality
defect (28). Situs inversus totalis is not
genetically predetermined in patients with
PCD, but occurs as a random phenomenon
due to nodal ciliary dysfunction during
embryogenesis (29, 30). More recently,
investigators have found an association
between PCD and heterotaxy (situs
ambiguus or organ laterality defects other
than situs inversus totalis) (31–33), which
is associated with increased morbidity
due to complex cardiovascular anomalies.
Therefore, patients with anomalies
consistent with situs ambiguus or
heterotaxy, including congenital heart
disease, who also have neonatal respiratory
distress or chronic respiratory tract
symptoms should be considered for
PCD evaluation.
Our data show that the remaining
three criteria-defined clinical features
(features 1–3), including neonatal
respiratory distress, are equally predictive
of PCD in patients with and without
laterality defects. Of note, patients who
have central apparatus defects, such as
those with biallelic mutations in RSPH4A
or RSPH9, do not have laterality defects,
presumably due to preserved left-to-right
flow across the embryonic node (8).
The upper respiratory tract is almost
universally involved, and early onset (age
<6 mo) of year-round nasal congestion is a
feature that distinguishes PCD from
non-PCD. Rhinosinusitis and otitis media
begin in early infancy in children with PCD
and are responsible for morbidity early in
life (3, 4). Many children with PCD have
a history of recurrent or persistent otitis
media requiring multiple antibiotic courses,
often with sequelae that include conductive
hearing loss and/or intervention with
repeated myringotomy tube placement.
However, chronic or recurrent otitis media
is prominent in children without PCD as
well. Therefore, middle ear disease did not
clearly discriminate subjects with PCD
from those without it in this study, though
absence of middle ear disease during early
childhood is inconsistent with a diagnosis.
Many PCD cases are not recognized
until late childhood or adulthood, after
bronchiectasis from chronic airway
infections occurs. Family history,
particularly in an older sibling, may prompt
diagnostic testing in infancy. However, most
patients do not have a positive family
history, as is true for other autosomal
recessive disorders. All four criteria-defined
clinical features in our panel are apparent in
the first year of life; therefore, specialists
evaluating children with chronic respiratory
symptoms or laterality defects could use
this panel to promote earlier recognition of
infants and young children likely to have
PCD, which would lead to earlier diagnosis.
For example, a pulmonologist evaluating
a young child for chronic respiratory
Table 5. Sensitivity and specificity based
on number of general clinical features
versus criteria-defined clinical features:
performance as test
Features Sensitivity Specificity
Number of general
clinical features
4 0.37 0.97
3 0.84 0.74
2 0.99 0.22
1 1.00 0.04
0 1.00 0.00
Number of criteria-
defined clinical
features
4 0.21 0.99
3 0.50 0.96
2 0.80 0.72
1 0.96 0.41
0 1.00 0.00
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Se
ns
iti
vi
ty
Figure 2. Receiver operating characteristic curves for the criteria-defined clinical features. The
unweighted receiver operating characteristic curve (solid curved line) uses a uniform weight for each
of the four significant criteria-defined clinical features. For the weighted curve (dashed line), each
clinical feature is weighted by its logistic regression parameter estimate from Table 3 (2.05 for laterality
defect, 1.89 for neonatal respiratory distress, 1.28 for nasal congestion, 1.13 for chronic cough and
0.01 for multiple ear infections). The areas under the curve were 0.86 (95% confidence interval,
0.82–0.89) for the weighted receiver operating characteristic curve and 0.84 (95% confidence
interval, 0.81–0.88) for the unweighted receiver operating characteristic curve. The weighted curve
was minimally better than the unweighted curve (P = 0.019), but the shape was similar except for the
region of sensitivity (50–80%).
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symptoms may recognize that a child with
early-onset wet cough and early-onset nasal
congestion may have PCD, even in the
absence of neonatal respiratory distress or
laterality defect. Similarly, a patient with
all four criteria-defined clinical features has
a high likelihood of PCD, even if diagnostic
testing is inconclusive. With further
validation and refinement, a panel based
on clinical features may have utility as a
diagnostic tool.
Strengths and Limitations
The strength of our findings is that we
designed a multicenter prospective study
with standardized data collection of the
clinical information, followed by rigorous
uniform application of a reference diagnosis
for PCD, including electron microscopy
of ciliary ultrastructure and molecular
genetic analyses. These diagnostic tests can
provide firm evidence for a PCD diagnosis,
but they may miss some cases. Molecular
genetic diagnosis is challenging because
of the extensive genetic heterogeneity.
Currently, mutations in 35 genes are
associated with PCD and account for
approximately 66% of all cases. Thus,
pathogenic mutations in novel genes or in
the regions not interrogated by testing
laboratories may be missed. Additionally,
not all of the 35 PCD-associated genes are
part of the panels that are being offered
in clinical molecular genetic testing
laboratories.
One limitation of our approach is
that the application of a rigorous reference
diagnosis resulted in exclusion of a large
proportion of our cohort (26%) that we
strongly suspect has PCD on the basis of
nasal nitric oxide testing. However, we
demonstrated in a sensitivity analysis
that inclusion of these unclassified
subjects as PCD cases yielded slightly
lower sensitivities but in similar ranges,
increasing confidence in the external
validity of our findings. A second limitation
is that we evaluated the accuracy of the
clinical criteria in a cohort referred for
suspicion of PCD. Thus, our results are not
necessarily generalizable to the general
population. Finally, owing to the rarity of
this disease, we have not yet applied our
clinical diagnostic criteria to a validation
cohort; however, this is a goal of future
research.
Conclusions
Four criteria-defined clinical features
(unexplained neonatal respiratory distress
with persistent supplemental oxygen
requirement in term infants; early-onset,
year-round wet cough; early-onset, year-
round nasal congestion; and laterality
defects) in combination are highly
effective in discriminating children and
adolescents who are likely to have PCD.
Conversely, the absence of these clinical
features should reduce the clinician’s
index of suspicion. The sensitivity and
specificity of these four criteria among
children referred for suspicion of
PCD indicate that they can be used to
identify at-risk children and direct
decisions regarding further diagnostic
testing. n
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